51 related articles for article (PubMed ID: 15816993)
21. Oxidative stress in primary glomerular diseases: a comparative study.
Markan S; Kohli HS; Sud K; Ahuja M; Ahluwalia TS; Sakhuja V; Khullar M
Mol Cell Biochem; 2008 Apr; 311(1-2):105-10. PubMed ID: 18219553
[TBL] [Abstract][Full Text] [Related]
22. Glomerular malondialdehyde levels in patients with focal and segmental glomerulosclerosis and minimal change disease.
Nezhad ST; Momeni B; Basiratnia M
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):886-91. PubMed ID: 20814126
[TBL] [Abstract][Full Text] [Related]
23. Increased glomerular and extracellular malondialdehyde levels in patients and rats with diabetic nephropathy.
Chang JM; Kuo MC; Kuo HT; Chiu YW; Chen HC
J Lab Clin Med; 2005 Oct; 146(4):210-5. PubMed ID: 16194682
[TBL] [Abstract][Full Text] [Related]
24. Alterations of glomerular and extracellular glutathione peroxidase levels in patients and rats with focal segmental glomerulosclerosis.
Chen HC; Guh JY; Lai YH
J Lab Clin Med; 2001 Apr; 137(4):279-83. PubMed ID: 11283522
[TBL] [Abstract][Full Text] [Related]
25. Minimal change disease and idiopathic focal segmental glomerulosclerosis in adults. A quantitative study.
Danilewicz M; Wagrowska-Danilewicz M
Pol J Pathol; 1996; 47(4):209-14. PubMed ID: 9097714
[TBL] [Abstract][Full Text] [Related]
26. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats.
Chen CA; Hwang JC; Guh JY; Chang JM; Lai YH; Chen HC
J Lab Clin Med; 2006 Feb; 147(2):74-82. PubMed ID: 16459165
[TBL] [Abstract][Full Text] [Related]
27. Increased glomerular and extracellular malondialdehyde levels in patients and rats with focal segmental glomerulosclerosis.
Kuo HT; Kuo MC; Chiu YW; Chang JM; Guh JY; Chen HC
Eur J Clin Invest; 2005 Apr; 35(4):245-50. PubMed ID: 15816993
[TBL] [Abstract][Full Text] [Related]
28. Pathophysiology of minimal change nephrotic syndrome and focal segmental glomerulosclerosis.
Cho MH; Hong EH; Lee TH; Ko CW
Nephrology (Carlton); 2007 Dec; 12 Suppl 3():S11-4. PubMed ID: 17995521
[TBL] [Abstract][Full Text] [Related]
29. Permeability factors in focal segmental glomerulosclerosis.
Savin VJ; McCarthy ET; Sharma M
Semin Nephrol; 2003 Mar; 23(2):147-60. PubMed ID: 12704575
[TBL] [Abstract][Full Text] [Related]
30. Focal segmental glomerulosclerosis and renal transplantation.
Crosson JT
Transplant Proc; 2007 Apr; 39(3):737-43. PubMed ID: 17445586
[TBL] [Abstract][Full Text] [Related]
31. Soluble urokinase receptor and focal segmental glomerulosclerosis.
Reiser J; Wei C; Tumlin J
Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):428-32. PubMed ID: 22569341
[TBL] [Abstract][Full Text] [Related]
32. Animal models of FSGS: lessons for pathogenesis and treatment.
Fogo AB
Semin Nephrol; 2003 Mar; 23(2):161-71. PubMed ID: 12704576
[TBL] [Abstract][Full Text] [Related]
33. Minimal change disease and idiopathic FSGS: manifestations of the same disease.
Maas RJ; Deegens JK; Smeets B; Moeller MJ; Wetzels JF
Nat Rev Nephrol; 2016 Dec; 12(12):768-776. PubMed ID: 27748392
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
